الفرق بين المراجعتين لصفحة: «ساكساغلبتين»

من موسوعة العلوم العربية
اذهب إلى التنقل اذهب إلى البحث
(نقل النص للترجمة)
 
(إخفاء النص الإنكليزي لترجمته لاحقاً بكود <!-- -->)
سطر 50: سطر 50:
| StdInChIKey = QGJUIPDUBHWZPV-SGTAVMJGSA-N
| StdInChIKey = QGJUIPDUBHWZPV-SGTAVMJGSA-N
}}
}}
 
الساكساغلبتين {{إنج|Saxagliptin}} ([[International Nonproprietary Name|rINN]]) سمي سابقاً  '''BMS-477118''' وهو دواء فموي لمرض السكري من مثبطات DPP-4
<!--
'''Saxagliptin''' ([[International Nonproprietary Name|rINN]]), previously identified as '''BMS-477118''', is a new oral hypoglycemic ([[anti-diabetic drug]]) of the new [[DPP-4 inhibitors|dipeptidyl peptidase-4 (DPP-4) inhibitor]] class of drugs.<ref name="ahren">{{cite journal | author = Augeri D ''et al.''
'''Saxagliptin''' ([[International Nonproprietary Name|rINN]]), previously identified as '''BMS-477118''', is a new oral hypoglycemic ([[anti-diabetic drug]]) of the new [[DPP-4 inhibitors|dipeptidyl peptidase-4 (DPP-4) inhibitor]] class of drugs.<ref name="ahren">{{cite journal | author = Augeri D ''et al.''
  | title = Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
  | title = Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
سطر 141: سطر 142:
*[http://www.forbes.com/2004/01/26/cx_mh_rl_diabetestearsheet_5.html The race to get DPP-4 inhibitors to market] - Forbes.com
*[http://www.forbes.com/2004/01/26/cx_mh_rl_diabetestearsheet_5.html The race to get DPP-4 inhibitors to market] - Forbes.com
*{{cite web|url=http://www.medpagetoday.com/Washington-Watch/Washington-Watch/13555|title=Saxagliptin First Diabetes Drug to Pass FDA Cardiovascular Safety Review|last=Walker|first=Emily P.|work=}}
*{{cite web|url=http://www.medpagetoday.com/Washington-Watch/Washington-Watch/13555|title=Saxagliptin First Diabetes Drug to Pass FDA Cardiovascular Safety Review|last=Walker|first=Emily P.|work=}}
-->
{{بذرة}}
{{بذرة}}
{{Oral hypoglycemics}}
{{Oral hypoglycemics}}

مراجعة 10:23، 27 مارس 2013

ساكساغلبتين
Systematic (IUPAC) name
(1S,3S,5S)-2-[(2S)-2-amino-2-(3-hydroxy-1-adamantyl)
acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile
Clinical data
AHFS/Drugs.com Consumer Drug Information
MedlinePlus a610003
Licence data EMA:LinkUS FDA:link
Pregnancy cat. ?
Legal status POM (UK) -only (US)
Routes Oral
Identifiers
CAS number 361442-04-8 N
ATC code A10BH03
PubChem CID 11243969
DrugBank DB06335
ChemSpider 9419005 YesY
UNII 8I7IO46IVQ N
ChEMBL CHEMBL385517 YesY
Chemical data
Formula C18H25N3O2 
Mol. mass 315.41 g/mol
 N (what is this?)  (verify)

الساكساغلبتين (بالإنجليزية: Saxagliptin) (rINN) سمي سابقاً BMS-477118 وهو دواء فموي لمرض السكري من مثبطات DPP-4